Albany Molecular Research is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.
Show more
Type
Public
HQ
Albany, US
Founded
1991
Size (employees)
3,085 (est)
Albany Molecular Research was founded in 1991 and is headquartered in Albany, US
Report incorrect company information

Albany Molecular Research Office Locations

Albany Molecular Research has an office in Albany
Albany, US (HQ)
26 Corporate Cir
Show all (1)
Report incorrect company information

Albany Molecular Research Financials and Metrics

Albany Molecular Research Financials

Albany Molecular Research's revenue was reported to be $570.45 m in FY, 2016 which is a 41.8% increase from the previous period.
USD

Revenue (Q2, 2017)

172.9 m

Net income (Q2, 2017)

(10.2 m)

EBIT (Q2, 2017)

(1.6 m)

Market capitalization (31-Aug-2017)

928.3 m

Cash (30-Jun-2017)

42.2 m

EV

906.9 m
Albany Molecular Research's current market capitalization is $928.3 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

246.6 m276.6 m402.4 m570.5 m

Revenue growth, %

12%45%42%

EBIT

20.2 m5.7 m13.6 m(18.8 m)

EBIT margin, %

8%2%3%(3%)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

60.8 m59.3 m68.2 m62.5 m81.8 m89.5 m104.6 m105.6 m120.8 m152.7 m163.8 m172.9 m

General and administrative expense

9.2 m10.6 m12.7 m11.6 m17.5 m16.5 m21.2 m24.6 m27.9 m37.3 m33.4 m38.6 m

R&D expense

94 k79 k128 k568 k490 k384 k1.9 m3.2 m3.5 m4.6 m3.4 m3.5 m

Operating expense total

54.7 m51.9 m63.1 m72.2 m80.6 m83.4 m104.6 m109.7 m114.3 m168.4 m161.7 m174.5 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

175.9 m47 m49.3 m52 m

Accounts Receivable

52.2 m71.6 m110.4 m144.8 m

Inventories

7.1 m11 m16.2 m167.1 m

Current Assets

279 m191 m280.2 m392.9 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

39.7 m166.6 m130.4 m18.4 m28.5 m42.6 m79.5 m44.2 m30.7 m44.8 m35.2 m42.2 m

Accounts Receivable

43.7 m58.1 m58.5 m56.2 m78.4 m79.1 m88.3 m96.1 m100.6 m126.9 m139.7 m139.3 m

Inventories

34.5 m35.3 m44.3 m56 m53.5 m60.6 m104.7 m94.1 m93.2 m201.9 m174 m186.4 m

Current Assets

138.4 m280.4 m260.8 m159 m189.8 m206.7 m303.4 m274 m256.7 m404.2 m385.2 m403.9 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

12.7 m(3.3 m)(2.3 m)(70.2 m)

Depreciation and Amortization

15.9 m18.4 m27 m50.6 m

Inventories

(5.1 m)(8 m)7.7 m21.5 m

Cash From Operating Activities

28.2 m1.9 m39.6 m26.6 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

3.9 m3.5 m3.7 m(8.6 m)(2.2 m)2.3 m(4.2 m)(10.1 m)(21.3 m)(23.4 m)(10.7 m)

Inventories

60.6 m104.7 m94.1 m93.2 m201.9 m174 m

Accounts Payable

49.5 m63.3 m73.7 m72.5 m127.4 m108.9 m
USDY, 2017

EV/EBIT

-582.8 x

Financial Leverage

3.9 x
Show all financial metrics
Report incorrect company information